List view / Grid view
6 August 2014 | By Yabao Pharmaceutical Co, Inc
Yabao Pharmaceutical Co, Inc. announced a strategic partnership with Changzhou Le Sun Pharmaceuticals Ltd.to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008, which currently is under pre-clinical development...
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
4 August 2014 | By Bristol-Myers Squibb Company
Allied Minds and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S...
4 August 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab, also known as ACTEMRA) has received a positive opinion from the Committee for Medicinal Products for Human Use for use in Europe...
4 August 2014 | By Boehringer Ingelheim & Zealand Pharma
Zealand Pharma and Boehringer Ingelheim jointly announced a new global exclusive licence, research and development collaboration...
28 July 2014 | By AstraZeneca
AstraZeneca announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291...
25 July 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig®...
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...
22 July 2014 | By AstraZeneca
AstraZeneca announced that MedImmune has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies...
21 July 2014 | By Teva
...opens door to a strong and novel migraine prevention and treatment franchise within its CNS portfolio.
18 July 2014 | By Amgen
Analysis shows study met primary and all secondary endpoints AMG 416 is a novel calcimimetic administered intravenously...
17 July 2014 | By Roche
Roche presented data from two phase II studies investigating whether crenezumab can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease...
17 July 2014 | By Pfizer
Pfizer Inc. and InnoPharma, Inc. announced that they have entered into an agreement under which Pfizer will acquire InnoPharma...
16 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease...
15 July 2014 | By Mundipharma EDO GmbH
Mundipharma EDO GmbH is pleased to announce strong preclinical activity in Multiple Myeloma with its lead small molecule compound EDO-S101...
